First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Status:
Terminated
Trial end date:
2018-04-24
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel
as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Matthew Galsky
Collaborators:
Hoosier Cancer Research Network Novartis Pharmaceuticals